IWS’s vision is to be a critical part of an integrated diabetic management ecosystem to improve patient quality of life. There are 22 million diagnosed diabetics, and 8 million undiagnosed diabetics, in the United States with an increase of 1.4 million patients per year. At some time during the course of the disease 1 in 4 patients will develop a Diabetic Foot Ulcer (DFU). For those patients that develop a DFU there is a 1 in 5 chance that it could lead to an amputation over the course of the disease.
The annual direct medical costs for DFUs are running at 12 billion dollars per year, with indirect medical costs running 6 billion dollars per year. In addition we have seen up to 80,000 amputations per year in diabetic patients. Amputations carry with them a 5 year mortality rate ranging from 39% - 80% (as high as the most aggressive forms of cancer).
IWS will utilize a Clinical Grade Smart Insole (CGSI) with a variety of sensor technologies to monitor conditions, detect abnormalities, and prevent the formation of Diabetic Foot Ulcers (DFUs). With embedded communication technology this device will provide vital actionable data to the heath care ecosystem.
The SmartSole system incorporates as its foundation a custom Clinical Grade insole with our Adaptive Human Suspension System AHSS. The system stabilizes the entire foot biomechanically and prevents rotation and friction which are major contributing factors to the creation of DFUs in diabetic patients.
The AHSS system is combined with our proprietary Patent Pending sensor systems which measures foot pressure thermometric differences in pressure, heat, and other vital signs. By incorporating Bluetooth BLE the data from these sensors can be linked thru a smart device to provide direct notification to the patient while concurrently notifying the healthcare management system. We are developing a tiered response system based on the International Working Group On The Diabetic Foot (IWGDF) risk classification system. Stay Tune!